Ameriprise
LYEL icon

Ameriprise’s Lyell Immunopharma LYEL Stock Holding History

Ameriprise’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,874
Closed -$24K – 4102
2024
Q4 		$24K Buy
+1,874
New +$37.1K ﹤0.01% 4041
2023
Q4 		– Sell
-2,247
Closed -$66.1K – 3947
2023
Q3 		$66.1K Buy
+2,247
New +$107K ﹤0.01% 3824
2023
Q2 		– Sell
-11,347
Closed -$536K – 3965
2023
Q1 		$536K Buy
+11,347
New +$607K ﹤0.01% 3408

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Ameriprise's LYEL Position: Q1 2025 in Review

Ameriprise sold out of Lyell Immunopharma (LYEL) in Q1 2025, closing a stake of 1,874 shares — an estimated $24K sold.

Ameriprise first reported a position in LYEL in Q1 2023 and held it in 3 quarters. The position peaked at $536K in Q1 2023. 112 funds tracked by Wall St. Rank hold LYEL as of Q1 2025.

  • Ameriprise reported no remaining Lyell Immunopharma position as of Q1 2025 after selling out during the quarter.
  • Ameriprise sold 1,874 Lyell Immunopharma shares in Q1 2025, an estimated $24K.
  • Ameriprise first reported a position in Lyell Immunopharma in Q1 2023 and held it in 3 quarters.
  • Ameriprise's Lyell Immunopharma position peaked at $536K in Q1 2023.
  • 112 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2025.

Based on Ameriprise's 13F filing for Q1 2025, filed 14 May 2025.